| NEKTAR THERAPEUTICS |
| USA |
| Gesundheit |
| US6402683063 / A419UB |
| ITH0 (Frankfurt) / NKTR (NASDAQ) |
| FRA:ITH0, ETR:ITH0, ITH0:GR, NASDAQ:NKTR |
| - |
| https://www.nektar.com/ |
|
Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States an..
>Volltext.. |
| 1956.61 Mio. EUR |
| 1874.43 Mio. EUR |
| 46.82 Mio. EUR |
| -109.99 Mio. EUR |
| -139.1 Mio. EUR |
| -8.67 EUR |
| 126.24 Mio. EUR |
| 2.71 Mio. EUR |
| -176.77 Mio. EUR |
| 4.59 |
| -50.54% |
| -21.57% |
| - |
| - |
| - |
| - |
| NEKTAR THERAPEUTICS, NEKTAR THERAPEUTIC |
| 15.04.26 |
|
||||
|